Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have ...
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage signaling that the company has succeeded in ...
Eli Lilly & Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, threatening to upend the many knockoffs that became popular when patients ...
Texas is suing insulin manufacturers and PBMs, including Eli Lilly and CVS Pharmacy, alleging a scheme to hike insulin prices ...
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...
Eli Lilly and Company LLY announced a significant $4.5 billion investment for the establishment of the Lilly Medicine Foundry in Indiana to advance drug production and innovation. This facility ...
Oct. 2 (UPI) --Eli Lilly said Wednesday it will invest $4.5 billion to build an advanced pharmaceutical drug manufacturing and development facility in Indiana expected to open in late 2027.
Drugmaker Eli Lilly said it will spend $4.5 billion to build a new manufacturing research hub in Indiana, where it will develop new methods of producing complicated types of medicines. The new investm ...
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback